Tasquinimod - Active Biotech

Drug Profile

Tasquinimod - Active Biotech

Alternative Names: ABR-215050; TASQ

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Active Biotech
  • Developer Active Biotech; Ipsen
  • Class Antineoplastics; Quinolines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Calgranulin B modulators; Immunomodulators; Thrombospondin 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Multiple myeloma; Prostate cancer

Highest Development Phases

  • Suspended Multiple myeloma
  • Discontinued Gastric cancer; Hepatocellular carcinoma; Ovarian cancer; Prostate cancer; Renal cancer

Most Recent Events

  • 15 Jan 2018 Active Biotech receives patent allowance for Tasquinimod in USA
  • 15 Nov 2017 Tasquinimod is available for licensing as of 09 Nov 2017. http://www.activebiotech.com/project-overview
  • 28 Aug 2017 Ipsen completes the phase II Umbrella trial for Renal cancer, Ovarian cancer, Gastric cancer & Hepatocellular carcinoma (Metastatic disease, Late-stage disease, Second-line therapy or greater) in United Kingdom, France, Belgium, Spain and Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top